The human equilibrative nucleoside transporter 1 (hENT1) is an important modulator of the physiological action of adenosine. We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. We identified Met89 and Ser160 as important in the affinity of hENT1 for various substrates and inhibitors. Mutation to Met89Cys or Ser160Cys significantly (p Ͻ 0.05) increased the S 6 -(4-nitrobenzyl)-mercaptopurine riboside (NBMPR) IC 50 values by approximately 4-and 6-fold, respectively (42 Ϯ 13 and 65 Ϯ 1.6 nM) compared with the wild-type transporter (11 Ϯ 0.7 nM). The double mutant Met89Cys/Ser160Cys synergistically increased the NBMPR IC 50 value to approximately 19-fold of that of the wild-type transporter. In contrast, compared with wild-type hENT1, the sensitivity to dipyridamole inhibition was significantly (p Ͻ 0.05) increased by only the Ser160Cys (ϳ2.6-fold) or the double mutant Met89Cys/Ser160Cys (ϳ4.7-fold) but not by the Met89Cys mutant. Mutation to Met89Cys or Ser160Cys increased the K m of adenosine (ϳ8-and 3-fold) and the K i of guanosine (ϳ6-and 2-fold). The double mutant increased both the K m value of adenosine and the K i value of guanosine by ϳ8-fold and seemed to confer no additional reduction in adenosine or guanosine affinity than that by mutation of Met89 alone. Together, these data indicate that transmembrane domains (TMDs) 2 (Met89) and 4 (Ser160) of hENT1 interact and are important in conferring sensitivity to NBMPR. In contrast, Ser160 and Met89 of hENT1, respectively, play a dominant role in conferring sensitivity to dipyridamole and adenosine/ guanosine affinity.
The endogenous nucleoside adenosine is an important regulator in autocrine and paracrine signaling through its interactions with adenosine receptors (A 1 , A 2A , A 2B , and A 3 ) located in the plasma membrane (Mubagwa and Flameng, 2001) . The extracellular adenosine concentration, and therefore its physiological and pharmacological activity, is modulated by nucleoside transporters that actively (concentrative nucleoside transporters) or facilitatively (equilibrative nucleoside transporters, ENTs) transport adenosine into the cell (Kong et al., 2004) . For example, ENTs modulate extracellular adenosine concentration at the adenosine receptors in ethanol-induced ataxia (Choi et al., 2004) , in adenosinemediated cardioprotection in ischemia/reperfusion injury (Chaudary et al., 2004; Taniguchi et al., 2004) , and in adenosine-mediated neuromodulation (Snell et al., 2004) . ENTs also transport a number of antiviral and anticancer drugs such as ribavirin (Jarvis et al., 1998) and gemcitabine (Mackey et al., 1998) . Therefore, a better understanding of the molecular mechanisms by which adenosine and other nucleosides (including nucleoside drugs) bind to and are translocated by nucleoside transporters may aid in the development of new drugs that either modulate adenosine availability to adenosine receptors or are improved antiviral or anticancer drugs.
hENT1, an equilibrative nucleoside transporter, is the most widely expressed member of the ENT family and is ubiquitously expressed (Pennycooke et al., 2001) including in the intestine (Chandrasena et al., 1997) and the kidney (Franco et al., 1990) . hENT1 has broad nucleoside substrate selectively (Ward et al., 2000) and has an affinity for adenosine in the low micromolar range (Ward et al., 2000) . hENT1 Article, publication date, and citation information can be found at http://molpharm.aspetjournals. org. doi:10.1124/mol.104.008102. is characterized by potent inhibition by NBMPR (Ward et al., 2000) and by inhibition by the non-nucleosides dipyridamole and dilazep (Visser et al., 2002) . A number of hENT1 amino acid residues have been identified which, when mutated, alter the affinity of hENT1 toward its substrates or inhibitors ( Fig. 1 and Table 1 ). Using two different yeast expression assays, our laboratory has identified a number of these amino acid residues (SenGupta et al., 2002; Endres et al., 2004) . The "adenosine rescue" assay is one of these and relies on the transport of extracellular adenosine by heterologously expressed hENT1 for yeast growth and survival. This assay can identify randomly generated hENT1 mutants that are capable of transporting adenosine despite the presence of the hENT1 inhibitors such as NBMPR, dipyridamole, or dilazep. In this article, we report the use of this adenosine rescue assay to identify hENT1 amino acid residues Met89 and Ser160 which, when either singly or simultaneously mutated, selectively reduce hENT1 affinity for adenosine or guanosine (but not other natural nucleosides) and hENT1 sensitivity to inhibition by NBMPR or dipyridamole but not dilazep. In addition, we have identified for the first time that these two residues seem to act synergistically in reducing the sensitivity of the transporter to NBMPR inhibition.
Materials and Methods

Screening of Random Mutants by Phenotypic Complementation.
We screened our library of randomly generated hENT1 expressed in yeast strain cyh2, 15, 112, for random mutants resistant to inhibition by NBMPR, dipyridamole, and dilazep in an adenosine rescue plate assay described previously (Endres et al., 2004) . In brief, the yeast cells transformed with random mutants were replica-plated onto GR-Ura-Ade [2% galactose, 1% raffinose, 1% yeast nitrogen base (Difco, Detroit, MI), and 1% amino acid mix-uracil-adenine) plates containing 0 or 150 M adenosine and the presence or absence of 2 M NBMPR, 50 M dipyridamole, or 10 M dilazep (Sigma-Aldrich, St. Louis, MO). These plates were incubated at 30°C for 4 days and scored for growth. The yeast-expressing random mutants that showed resistance to inhibition of adenosine complementation were identified, and the plasmid's contribution to the inhibitor-resistant phenotype was confirmed by rescreening. Candidate plasmids that successfully reproduced the plate assay phenotype were sequenced using the BigDye Terminator reaction kit (Applied Biosystems, Foster City, CA) and analyzed by the University of Washington DNA Sequencing and Gene Analysis Center (Seattle, WA).
Generation and Expression of hENT1 Point Mutants. hENT1 point mutations were kinetically characterized in the plasmid pCEs and expressed in the yeast strain YPL1 (MATa fui1⌬::HIS3, and HIS3⌬) (SenGupta et al., 2002) . Plasmid pCEs was created from the plasmid pABC3 containing the yeast PDR5 constitutive promoter (Nakamura et al., 2001) . In brief, the 2 M yeast origin of replication was amplified from the plasmid pYES (SenGupta et al., 2002) with overhanging EcoRI and XhoI restriction sites. This fragment was then ligated into plasmid pABC3 and cut with EcoRI and XhoI to create plasmid pCE1. The cDNA encoding hENT1 was amplified from pYES with HindIII and NotI overhanging restriction sites and ligated into pCE1 cut with HindIII and NotI. The single Met89Cys/Leu/Gln/Thr/Val and Ser160Asn/Cys and Met89Leu/ Ser160Asn (Leu/Asn), Met89Gln/Ser160Asn (Gln/Asn), Met89Thr/ Ser160Asn (Thr/Asn), Met89Val/Ser160Asn (Val/Asn), and Met89Cys/ Ser160Cys (Cys/Cys) double point mutants were created in the plasmid pCES by site-directed mutagenesis using the QuikChange SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA). The primers used to introduce point mutations at Met89 were 5Ј-ATGACCCTAGCCXXX-CTGCCCCTGCTGTTA-3Ј (sense) and 5Ј-TAACAGGGGCAGXXXG-GCACATAGGGTCAT-3Ј (antisense), where the underlined sense nucleotides were TGT, TTG, CAA, ACT, and GTT for mutation to cysteine, leucine, glutamine, threonine, and valine, respectively. The primers used to introduce point mutations at Ser160 were 5Ј-GCCATCCTG-CAGGGCXXXCTGTTTGGTCTGGCT-3Ј (sense) and 5Ј-AGCCAGAC-CAAACAGXXXGCCCTGCAGGATGGC-3Ј (antisense), where the underlined sense nucleotides were ATT and TGT for mutation to asparagine and cysteine, respectively. The primers used to create Thr387Ile were 5Ј-CCCCGCCGCTACATTGTGGTCTTCGAGCAC-3Ј (sense) and 5Ј-GTGCTCGAAGACCACAATCAGGTAGCGGCGGGG-3Ј (antisense). All plasmids were sequenced for fidelity and transformed into yeast strain YPL1.
3 H-Nucleoside Transport Experiments. Yeast strain YPL1 harboring plasmids containing wild-type and mutant hENT1 were grown overnight in 5 ml of SD-Ura liquid media by shaking at 30°C. These mid-late log growth-phase yeast cells were then pelleted, and the supernatant was then decanted and the pellet resuspended in an equivalent volume of transport buffer (10 mM HEPES, pH 7.4, 100 mM choline chloride, 2 mM KCl, 1 mM CaCl 2 , and 1 mM MgCl 2 ). Then, 200-l aliquots of this cell suspension were pelleted and the supernatant discarded; 200 l of transport buffer containing radiolabeled substrate (2 3 ml of transport buffer. Cells deposited on filter membranes were then solubilized with 5% Triton X-100, and the radioactivity on each filter was determined by scintillation counting (Tricarb 1600 Scintillation Counter; PerkinElmer Life and Analytical Sciences, Boston, MA). Uptake data were normalized to yeast cell concentration, which was determined by measuring the optical density at 600 nm of the cellular suspensions in transport buffer. The uptake of radiolabeled substrate caused by diffusion and nonspecific binding was subtracted from the net uptake values by performing control uptake reactions in the presence of 10 M NBMPR.
Percentage inhibition experiments were performed by the inclusion of various concentrations of inhibitors or competing substrates in the transport solutions. IC 50 experiments were conducted by including increasing concentrations of inhibitors NBMPR (0-10 M), dipyridamole (0-5 M), dilazep (0-1 M), or guanosine (0-3 mM) in the transport solutions.
Kinetic parameters were calculated as described previously by tracer displacement (Malo and Berteloot, 1991; Chenu and Berteloot, 1993; Endres et al., 2004) . In brief, increasing concentrations of unlabeled adenosine (0-2 mM) were included in the transport buffer, and the kinetics of substrate transport were calculated from the inhibition (tracer displacement) profile as described below.
Data Analysis. The Student's t test was used to compare transport values of wild-type and mutant transporters. IC 50 values were estimated by fitting the following modified Hill equation to background-subtracted transport velocity data using nonlinear regression (WinNonLin):
where E is the observed transport velocity, c is the inhibitor concentration, E max is the maximal inhibition of transport by the inhibitor, IC 50 is the inhibitor concentration at which 50% inhibition of transport is observed, and ␥ is the Hill coefficient. The t test using pooled variances was used to test the null hypothesis that the sum of the mean IC 50 values of the single mutations and the mean IC 50 value of the double mutant were equivalent (additive effect).
Kinetic parameters (V max and K m ) were estimated by fitting
to the tracer displacement data using nonlinear regression (WinNonLin), where * is the velocity of transport of the labeled nucleoside, S cold is the concentration of the unlabeled nucleoside, T is the concentration of the labeled nucleoside, and V max , K m , and K d (diffusion constant) are the transport parameters. The guanosine K i value was estimated using the method of Cheng and Prusoff (1973) assuming competitive inhibition of adenosine by guanosine:
where S is the substrate concentration. The guanosine IC 50 value and adenosine K m value for the various transporters were experimentally determined as described above. Because [S] Ͻ Ͻ K m in our experimental protocol, eq. 3 reduces to K i Ϸ IC 50 .
Results
Screening of Random Mutant Libraries and Identification of Met89 and Ser160. Using our adenosine rescue assay, we screened our library of randomly generated hENT1 mutants for mutations that rendered hENT1 resistant to inhibition by NBMPR, dipyridamole, or dilazep. This screening assay used plates containing 0 or 150 M adenosine and 150 M adenosine plus 2 M NBMPR, 50 M dipyridamole, or 10 M dilazep. NBMPR, dipyridamole, and dilazep are well-known competitive inhibitors of hENT1, and we have shown previously that these concentrations prevent adenosine rescue in yeast expressing wild-type hENT1 yet allow for the detection of random mutants expressing inhibitor-resistant hENT1. As expected, in the absence of 150 M adenosine, neither the wild-type transporter nor the random mutant candidate NDDC8 grew, whereas in the presence of 150 M adenosine, both transported sufficient adenosine to overcome the ade2 phenotype and grew (Fig. 2 ). In addition, 2 M NBMPR, 50 M dipyridamole, and 10 M dilazep prevented adenosine rescue in yeast expressing wild-type hENT1, whereas yeast candidate NDDC8 grew strongly in the presence of 2 M NBMPR or 50 M dipyridamole and weakly in the presence of 10 M dilazep (Fig. 2) . This suggested that an amino acid change (or changes) in this random mutant contributed to a reduced affinity for these inhibitors.
Sequencing of the random mutant candidate NDDC8 identified three amino acid changes: Met89Thr, Ser160Asn, and Thr387Ile. We individually created these amino acid changes and expressed these hENT1 mutants in yeast strain YPL1 for kinetic characterization. Met89Thr or Ser160Asn transporters were significantly resistant to inhibition by NBMPR or dipyridamole compared with the wild-type transporter (Fig. 3) . In addition, all three mutants were significantly resistant to inhibition by dilazep, although the degree of difference in the Thr387Ile mutant was much smaller than that in the Met89Thr and Ser160Asn mutant. This suggested that mutation of both Met89Thr and Ser160Asn, but not Thr387Ile, contributed to the resistant phenotype in the plate assay toward NBMPR and dipyridamole (Fig. 4) . Characterization of the Inhibition of Yeast Expressing Met89 or Ser160 Mutations by hENT1 Inhibitors. In addition to Met89Thr and Ser160Asn, we created and characterized conserved (Met89Leu and Met89Val) and nonconserved (Met89Gln) mutations in hENT1 at this position. We also characterized the mutations Met89Cys and Ser160Cys to investigate the accessibility of these amino acid residues to sulfhydryl reactive reagents. Because the resistance to inhibition of [ 3 H]adenosine transport by the Met89Thr and Ser160Asn in the presence of 10 nM NBMPR seemed to be the greatest, we then investigated the inhibitory capacities (IC 50 values) of NBMPR toward wild-type and mutant hENT1-mediated [ 3 H]adenosine transport. The NBMPR IC 50 values of the Met89Cys, threonine, and valine mutants and Ser160Asn and cysteine single mutants were 1.6-to 7.5-fold greater and significantly different from that of the wild-type protein, whereas the IC 50 values of Met89Leu and glutamine showed that these mutants were approximately 2-to 3-fold more sensitive to NBMPR inhibition (Table 2) .
We then created and characterized the effect of simultaneous mutation at Met89 and Ser160 on NBMPR. We were surprised to find that the simultaneous mutation of Met89 and Ser160 to cysteine/cysteine resulted in a 19-fold reduction in NBMPR sensitivity compared with the wild-type transporter (Table 2) . We investigated whether the 19-fold increase in NBMPR IC 50 value (210 Ϯ 77.1 M) in the double mutant could be explained by an additive effect of the two single amino acid changes (3.7-and 5.8-fold increase to 41.6 Ϯ 13.1 and 65.0 Ϯ 1.55 M, respectively). The reduction of affinity (19-fold increase in IC 50 value) of NBMPR for hENT1 in the double mutant was approximately 2-fold greater and significantly different from that of the additive effect (9. ances) . This indicates that the increase in NBMPR IC 50 value in the double mutant is significantly greater than that expected by the additive effect of the individual mutations and suggests a synergistic interaction between these amino acid residues when mutated to cysteine. When the Met89 mutations leucine, glutamine, threonine, and valine were simultaneously mutated with Ser160Asn, the NBMPR IC 50 value was increased approximately 1.2-to 7.7-fold.
We further characterized the IC 50 values of dipyridamole and dilazep in the Met89Cys, Ser160Cys, and Met89Cys/ Fig. 2 . Phenotypic complementation plate assay. Plasmids were expressed in yeast strain W303-1A, spotted on a master plate (SD-Ura), and replica-plated in media in the absence (AϪ) or presence (Aϩ) of 150 M adenosine or 150 M adenosine and the following hENT1 inhibitors: 2 M NBMPR (NB), 50 M dipyridamole (DP), or 10 M dilazep (DZ). Shown are the growths after 4 days of incubation at 30°C of wild-type hENT1 and the random mutant candidate NDDC8 containing the amino acid changes Met89Thr, Ser160Asn, and Thr387Ile. Unlike wild-type hENT1, this random mutant candidate shows growth in the presence of NBMPR or dipyridamole but not in the presence of dilazep. 6 cells/min for wild type, Met89Thr, Ser160Asn, and Thr387Ile, respectively). Significant differences (p Ͻ 0.05) from the wild-type transporter are indicated by an asterisk. These data suggest that Met89 and Ser160 but not Thr387 substantially contribute to the NBMPR-and dipyridamole-resistant phenotype of NDDC8 on the plate assay. Fig. 4 . Multiple sequence alignment of human, mouse, rat, and rabbit ENT1, ENT2, ENT3, and ENT4. Sequences were aligned using ClustalW multiple-sequence alignment and the GONNET similarity matrix. The sequences were obtained from GenBank and had the following accession numbers: hENT1 (AF079117), rENT1 (NM_031684), mENT1 (AF218255), hENT2 (AF034102), rENT2 (NM_031738), mENT2 (AF183397), rbENT2 (AF323951), hENT3 (AF326987), mENT3 (AF326986), and hENT4 (NM_153247). Amino acid numbering is relative to hENT1. Met89 and Ser160 in hENT1 are shown in boldface type along with aligned homologous amino acids. Amino acid residue 89 is conserved as methionine in ENT1 and glutamine in ENT2 across the species shown, whereas Ser160 is highly conserved among all ENTs and species shown. Putative hENT1 TMDs 2 and 4 are underlined and were determined by the consensus predictions of five algorithms (TMPRED, TopPred2, TMHMM, HMMTop, and SOSUI). ]adenosine transport by all three mutants were 1.4-to 3.9-fold that of the wild-type transporter, but these differences were not statistically significant.
Characterization of the Inhibition and Kinetics of Natural Nucleoside Transport by Met89 and Ser160 Point Mutations. We then characterized the effect of the single and double point mutations at Met89 and Ser160 on the kinetics of various natural nucleosides. We first investigated the ability of the purines adenosine, guanosine, and inosine and pyrimidines uridine, cytidine, and thymidine to inhibit (Fig. 5) . In addition, yeasts expressing the double mutant were also marginally but significantly resistant to inhibition by low (200 M) concentrations of uridine and both low and high (600 M and 2 mM) concentrations of thymidine. At the high concentrations, the magnitude of this resistance to inhibition was not large; therefore, we chose to further characterize the kinetics of transport of the purines adenosine and guanosine.
Because the inhibition by adenosine was most affected by Met89 and Ser160 mutations, we characterized in detail the kinetics of adenosine transport by the wild-type and these mutant transporters. Yeast expressing the Met89Cys and Met89Cys/Ser160Cys mutants had an approximate 8-fold and statistically significant increase in adenosine K m value, whereas the Ser160Cys single mutant had an approximate 3-fold increase in adenosine K m value ( In addition, the adenosine K m and guanosine K i values of the Met89Cys single mutant were not significantly different from those of the Met89Cys/Ser160Cys double mutant (p Ͼ 0.05).
Discussion
Using the adenosine rescue assay, we identified one random mutant hENT1 candidate (NDDC8) containing nonsynonymous amino acid changes at Met89Thr, Ser160Asn, and Thr387Ile. When we created these mutations individually, we found that the mutation at Met89 or Ser160 contributed to the resistance of hENT1 to inhibition by NBMPR, dipyridamole, or dilazep, whereas mutation at Thr387 did not contribute to resistance to NBMPR or dipyridamole but did contribute marginally to resistance to dilazep (Fig. 3) .
Methionine is conserved at amino acid residue 89 in all mammalian ENT1s, whereas it is glutamine and threonine in the mammalian ENT2s and ENT3s. In contrast, Ser160 is conserved among all mammalian ENTs. To investigate the mechanisms by which these amino acids apparently reduced inhibitor affinity, we created various amino acid changes at these positions. At Met89, we created the amino acid residues present in hENT2 and hENT3 (glutamine and threonine, respectively). We also created substitutions of Met89 to valine (sterically conserved, but slightly more nonpolar than threonine), leucine (conserved), and cysteine. At Ser160, we created a sterically conserved, yet slightly more nonpolar, change from serine to cysteine. Then, we characterized in detail the inhibition by NBMPR of [ 3 H]adenosine transport in yeast expressing these various mutations at Met89 and Ser160. We focused on NBMPR, because only NBMPR is a nucleoside analog, whereas dipyridamole and dilazep are structurally unrelated to nucleosides. Substitution of Met89 to leucine or glutamine increased the sensitivity of these transporters to NBMPR, whereas substitution to cysteine or threonine decreased the sensitivity to NBMPR, and substitution to valine had very little effect on this sensitivity. Because theronine and valine are sterically very similar in size and differ in only a hydroxyl group, this suggests that the reduction of NBMPR affinity in the Met89Cys mutant is caused not by a steric effect of this mutation in the transporter but by that of the threonine hydroxyl group. This is similar to our observation with Ser160. The sterically conserved substitution of serine to cysteine also decreased the sensitivity to inhibition by NBMPR, suggesting that this is not a result of a steric impact on the protein structure.
We created the cysteine substitutions with the intent to investigate the accessibility of these amino acid residues to various sulfhydryl reagents. Unfortunately, various undetermined endogenous cysteines were reactive to these reagents, and we were unable to detect any differential reactivity between the wild-type transporter and the mutant transporters containing the cysteine substitutions. Despite this, we were surprised to find that the NBMPR IC 50 value of yeast expressing the simultaneous mutation Met89Cys/Ser160Cys was approximately 2-fold greater and significantly different from what we would have expected from the additive effect of the individual mutations. We also characterized the effect of simultaneous mutation of Ser160Asn with the other Met89 substitutions. The Met89Leu mutation (which alone increased NBMPR affinity ϳ3-fold) seems to "counteract" the reduced NBMPR affinity that Ser160Asn contributes to, whereas the Met89Gln mutation does not. The Ser160Asn mutation seems to be dominant over the Met89Val mutation (which alone did not substantially contribute to a reduction in NBMPR affinity), whereas the reduction in NBMPR affinity in the Met89Thr/Ser160Asn mutant is essentially no different for either of the Met89Thr or Ser160Asn single substitutions.
We also characterized the effect of the single and simultaneous cysteine substitutions on dipyridamole and dilazep sensitivity. Consistent with what we observed in the plate assay and single concentration inhibition experiments with Met89Thr and Ser160Asn, the IC 50 values of dipyridamole toward the Ser160Cys and the cysteine/cysteine mutants were increased, whereas none of the IC 50 values for dilazep were significantly different from that of the wild-type transporter. Unlike NBMPR, Met89Cys mutation did not significantly decrease the ability of dipyridamole to inhibit hENT1, whereas the mutation Ser160Cys did. These data suggest that Ser160 is important for the interaction of dipyridamole with hENT1, whereas both Met89 and Ser160 are important for the interaction of NBMPR with hENT1.
Upon characterizing the ability of various natural nucleosides to inhibit [ 3 H]adenosine transport, we found that the ability of both low and high concentrations of adenosine and guanosine to inhibit [ 3 H]adenosine transport by hENT1 was reduced. Characterization of the transport kinetics of these two substrates for the mutant transporters revealed that substitution of Met89 to cysteine was sufficient to reduce the affinity (K m ) of adenosine approximately 8-fold but increased the V max by approximately 3-fold. In contrast, Ser160Cys mutations had a significant but smaller (ϳ3-fold) effect on the K m of adenosine transport. The double mutant Met89Cys/ Ser160Cys, however, demonstrated a K m value for adenosine ]guanosine by the single-and double-mutant transporter was not high enough for determination of its transport kinetics. Instead, we estimated the inhibitory capacity (K i ) of guanosine toward adenosine transport as a measure of its affinity for the transporter. As was the case for adenosine, substitution of Met89 to cysteine was the dominant mutation and reduced the "affinity" of guanosine approximately 6-to 8-fold.
The synergistic effect of simultaneous mutation of Met89 and Ser160 to cysteine suggests that these substituted residues interact (either directly or indirectly) to reduce NBMPR affinity. It has been suggested that in this situation, direct interaction between the inhibitor functional groups that interact with these amino acid residues can be identified by structure-activity studies of various inhibitor analogs (Kristensen et al., 2004) . Our data indicate that the affinity of both adenosine and guanosine is not synergistically decreased in the double mutant and that Met89 is the dominant contributor to the reduction in affinity for these substrates. Because the affinity of inosine and the pyrimidines was not affected, this suggests that Met89 interacts with the purine ring of adenosine, guanosine, and NBMPR. In addition, this suggests that mutation of Ser160 alters the interaction of the nitrobenzylthiol group of NBMPR with the transporter, because mutation of Ser160 did not have any effect on any natural nucleosides affinity. To determine the specific functional groups of NBMPR that interact with Ser160, structure-activity studies with various NBMPR analogs must be conducted. These analogs have been described previously (Deghati et al., 2003) , although none was available to us. It is possible that we did not observe the synergistic effect with Met89/Ser160Asn double mutations because the Ser160Asn substitution is sterically unconserved and may therefore introduce gross structural changes in the protein structure. On the other hand, substitution of both Met89 and Ser160 to cysteine introduces only subtle changes, which are unlikely to grossly alter the transporter structure.
Our data suggest that Met89 and Ser160 interact either directly or indirectly to alter NBMPR affinity. Met89 is in putative TMD 2, whereas Ser160 is in putative TMD 4. Previous studies have implicated other amino acid residues within these TMDs which when mutated have an effect on NBMPR and substrate affinity ( Fig. 1 and Table 1) . Our laboratory has shown that mutation of Leu92 (in TMD 2) increases the IC 50 value of NBMPR and dilazep approximately 220-and 4-fold, respectively (Endres et al., 2004) . In addition, this mutation increases the K m value (reduced the affinity) of inosine but not adenosine approximately 4-fold compared with the wild-type transporter. Because helicalwheel analysis predicts that Leu92 and Met89 are on the same face of TMD 2, this is consistent with a model whereby Met89 directly interacts with the purine ring of adenosine, guanosine, and NBMPR and Leu92 directly interacts with the purine ring of inosine and NBMPR. Our group also characterized the effect of mutation of Gly154 (in TMD 4) to serine (the homologous amino acid residue in hENT2) and found that this increases the IC 50 value for NBMPR, dipyridamole, and dilazep approximately 2500-, 3-, and 7-fold, respectively, and reduces the affinity of adenosine and cytidine approximately 3-fold (SenGupta and Unadkat, 2004).
Although helical-wheel prediction expects Ser160 and Gly154 to be on nearly on opposite faces of the ␣ helix, TMD 4 is clearly important in NBMPR binding. This work demonstrates for the first time the effect of simultaneous mutation of amino acid residues in these TMDs. It is possible that these TMDs are in proximity in the packing of the ␣-helices that form the tertiary structure of hENT1, and our observation of the synergistic effect of simultaneous mutation of Met89 and Ser160 on NBMPR affinity is a result of this. Indeed, while this work was under review, Arastu-Kapur et al. proposed a putative helical packing model of the ENT family in which TMDs 2 and 4 are adjacent and part of the putative aqueous pore (Arastu-Kapur et al., 2004) .
In conclusion, we have shown for the first time that Met89 (TMD 2) and Ser160 (TMD 4) are synergistically important in the inhibition of hENT1 by NBMPR, suggesting that these TMDs interact. In contrast, Ser160 seems to play a dominant role in the ability of dipyridamole to inhibit hENT1, whereas Met89 plays a dominant role in the affinity of hENT1 for adenosine and guanosine. Identification of additional such critical amino acid residues will be necessary to validate a proposed model of the putative binding site(s) of hENT1 inhibitors and substrates. Building such a model is critical for developing drugs that target this transporter, an important physiological and pharmacological modulator of the effects of adenosine.
